Biologics CDMO · Antibody development · Commercial manufacturing
WuXi Biologics
A global biologics CDMO providing development and manufacturing for antibody and other biopharmaceutical drugs. Hang Seng Index constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
Business categories Biopharma Manufacturing & CDMO · Biopharma & Life Sciences · primary
Other companies in the same category
- Biopharma Manufacturing & CDMO: Fujifilm Holdings · Samsung Biologics · ST Pharm · WuXi AppTec · Thermo Fisher Scientific
2269.HK Updated Jul 11, 2026 4 AI consumers· 3 recurring
Annual return · 2026-09-04'21-30.7%'22-13.7%'23-68.6%'24-10.1%'25+100.9%YTD+32.9%
Money in ▸·
WuXi Biologicsapprox. CN¥17.0B
▸ Money out·
Financials & Segments
- Total revenue · approx. CN¥17.0B (FY2023)
- Segments · Pre-IND (early development) · Post-IND (late-stage & commercial)
Revenue from
No refined links yet.
Pays to
No refined links yet.